ERA4TB, an international consortium to accelerate the development of comprehensive treatments against tuberculosis
The ERA4TB (European Regimen Accelerator for Tuberculosis) project is a public-private initiative dedicated to the development of drugs against tuberculosis. With a team of more than thirty organizations and a budget of over 200 million euros ERA4TB will focus on developing a new, improved tuberculosis treatment. The partners will share their expertise, knowledge and resources to rapidly progress new candidate drugs into clinical trials.
Merry Christmas from grit42. And Marvin.
We wish all of our customers, partners, family, friends, and depressed robots a very merry Christmas and a happy new year!
New IMI project “COMBINE” launched to accelerate the fight against antimicrobial resistance
11 European partners today announced that they are launching a new project, The Collaboration for Prevention and Treatment of Multi-Drug Resistant Bacterial Infections (COMBINE), under the IMI AMR Accelerator Programme. COMBINE will support projects in the AMR Accelerator with effective management, communication, and data capture capabilities, and carry out research to strengthen the scientific basis in the AMR field. COMBINE is funded by IMI, a joint initiative between the European Commission (EC) and the European Federation of Pharmaceutical Industries and Associations (EFPIA). COMBINE receives EUR 8 million from the EC; EFPIA in-kind contributions total EUR 17 million.
Strengthening our commitment to help tackle antimicrobial resistance, we’re joining the BEAM Alliance
Today, the digital laboratory specialists, grit42, joins the BEAM (Biotech companies in Europe combating AntiMicrobial Resistance) Alliance.